Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Exclusion Criteria

• •Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 \[HIV 1, HIV 2\] antibody) or hepatitis B or C viral infection.
• •Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening.
• •Inability of the participant, or the participant's legal guardian, to provide informed consent.
• •Pregnant, breastfeeding, or intending to conceive during the course of the study.
• •Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions).
• •The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham \[JC\] virus), parvovirus, or Epstein Barr virus.
• •The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis.
• •The participant has had or is required to have any live vaccination within 1 month prior to enrollment.